Lemaitre Vascular (LMAT) Cost of Revenue (2010 - 2026)

Lemaitre Vascular (LMAT) has reported Cost of Revenue for 17 consecutive years, with $18.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue fell 1.6% year-over-year to $18.2 million; the TTM figure through Mar 2026 stood at $70.8 million (changed 0.24% YoY), while the FY2025 annual figure was $71.1 million, up 3.05% from the prior year.
• Cost of Revenue slipped to $18.2 million in Q1 2026 per LMAT's latest filing, from $18.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $19.3 million in Q2 2025 and bottomed at $13.6 million in Q1 2022.
• Historically, Cost of Revenue has averaged $16.6 million across 5 years, with a median of $16.8 million in 2024.
• Annual changes were most pronounced in 2023 — Cost of Revenue rose 26.09% — and 2025, when it dropped 14.45%.
• Lemaitre Vascular's Cost of Revenue stood at $14.9 million in 2022, then advanced by 4.82% to $15.6 million in 2023, then gained by 9.66% to $17.1 million in 2024, then rose by 6.63% to $18.3 million in 2025, then fell by 0.59% to $18.2 million in 2026.
• Business Quant data shows LMAT's Cost of Revenue at $18.2 million in Q1 2026, $18.3 million in Q4 2025, and $15.1 million in Q3 2025.